GlassScriptPhysician profile
Tamjeed Arshad
NPI 1568492544
$36,661.22
in general payments reported to CMS, 2019-2025
44 companies · $1,260 in 2025
The $1,260 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,102 · 2020: $6,010 · 2021: $8,234 · 2022: $6,612 · 2023: $3,753 · 2024: $2,690 · 2025: $1,260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,942 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,750 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,942.29 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,750.00 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $25,472.25 | 2019-2025 | Lifevest |
| Abbott Laboratories | $2,953.00 | 2019-2025 | Gallant, Cardiomems, Perclose Prostyle |
| Medtronic, INC. | $1,147.93 | 2021-2025 | Micra, Linq II, Amplia Mri Quad Crt-D Surescan |
| Pfizer INC. | $998.57 | 2019-2025 | |
| Medtronic Vascular, INC. | $679.31 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $634.54 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $558.76 | 2019-2023 | Xarelto |
| Edwards Lifesciences Corporation | $475.75 | 2022-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| E.R. Squibb & Sons, L.L.C. | $473.23 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $395.61 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $299.16 | 2022-2025 | Verquvo, Capvaxive |
| Lexicon Pharmaceuticals, INC. | $256.17 | 2023-2024 | Inpefa |
| Boston Scientific Corporation | $240.50 | 2021-2023 | Watchman Access System |
| Alnylam Pharmaceuticals INC. | $211.14 | 2022-2025 | Amvuttra |
| Astrazeneca Pharmaceuticals LP | $204.02 | 2019-2025 | Wainua, Farxiga |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamjeed Arshad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.